### Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

### VERTEX PHARMACEUTICALS INC / MA

Form 4

September 23, 2014

September 2												
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								OMB APPROVAL				
								Number:	3235-0287			
Check the character of	ger so STATE 16.	MENT OF	CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES						Estimated average burden hours per			
Form 4 or Form 5 obligations may continue.  See Instruction 1(b).  Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940												
(Print or Type Responses)												
Silva Paul M Sym				Issuer Name <b>and</b> Ticker or Trading mbol				5. Relationship of Reporting Person(s) to Issuer				
			VERTEX PHARMACEUTICALS INC / MA [VRTX]					(Check all applicable)				
(Last)	(Last) (First) (Middle)				ransaction			Director 10% Owner Officer (give title Other (specify below)				
C/O VERT			09/19/2	014				SVP & Corp Controller				
PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE												
				Amendment, Date Original Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
BOSTON,	MA 02210							Form filed by M Person	Iore than One Re	porting		
(City)	(State)	(Zip)	Tabl	e I - Non-D	Derivative S	Securi	ities Acqu	uired, Disposed of	, or Beneficial	ly Owned		
1.Title of Security (Instr. 3)	2. Transaction Da (Month/Day/Year	Execution any	Date, if	if Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) Bene ar) (Instr. 8)  (A)  Securing Bene General (D) Securing Bene General (A)  Securing Bene General (A)				5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code V	Amount	or (D)	Price	(Instr. 3 and 4)				
Common Stock	09/19/2014			M	938	A	\$ 39.05	17,938	D			
Common Stock	09/19/2014			M	1,407	A	\$ 33.82	19,345	D			
Common Stock	09/19/2014			M	2,813	A	\$ 38.8	22,158	D			
Common Stock	09/19/2014			M	3,375	A	\$ 51.75	25,533	D			

### Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

Common Stock	09/19/2014	M	3,375	A	\$ 37.86	28,908	D	
Common Stock	09/19/2014	M	3,375	A	\$ 48.74	32,283	D	
Common Stock	09/19/2014	M	10,125	A	\$ 45.11	42,408	D	
Common Stock	09/19/2014	S(1)	25,408	D	\$ 99.85	17,000	D	
Common Stock						169	I	401(k)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 5. Number of TransactionDerivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 39.05	09/19/2014		M	938	(2)	02/03/2020	Common Stock	938
Stock Option (right to buy)	\$ 33.82	09/19/2014		M	1,407	(2)	07/13/2020	Common Stock	1,407
Stock Option (right to buy)	\$ 38.8	09/19/2014		M	2,813	(3)	02/02/2021	Common Stock	2,813
Stock Option (right to buy)	\$ 51.75	09/19/2014		M	3,375	<u>(4)</u>	07/12/2021	Common Stock	3,375

#### Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

Stock Option (right to buy)	\$ 37.86	09/19/2014	M	3,375	(5)	02/01/2022	Common Stock	3,375
Stock Option (right to buy)	\$ 48.74	09/19/2014	M	3,375	<u>(6)</u>	07/24/2022	Common Stock	3,375
Stock Option (right to buy)	\$ 45.11	09/19/2014	M	10,125	<u>(7)</u>	02/04/2023	Common Stock	10,125

# **Reporting Owners**

Reporting Owner Name / Address

Director 10% Owner Officer Other

Silva Paul M C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON, MA 02210

SVP & Corp Controller

# **Signatures**

Kenneth L. Horton, Attorney-In-Fact 09/23/2014

\*\*Signature of Reporting Person Date

## **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1.
- (2) Fully vested.
- (3) The option vests in 16 quarterly installments from 02/03/2011.
- (4) The option vests in 16 quarterly installments from 07/13/2011.
- (5) The option vests in 16 quarterly installments from 02/02/2012.
- (6) The option vests in 16 quarterly installments from 07/25/2012.
- (7) The option vests in 16 quarterly installments from 02/05/2013.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 3